Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PATH-HOME: Tezepelumab Device Functionality in Severe Asthma
NCT03968978Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- May 2019
- Primary completion
- Jun 2020
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
A Phase 3 trial of tezepelumab in severe asthma, sponsored by AstraZeneca. Started May 2019; status: completed.
02
Drugs
03
Conditions
severe asthma
Beyond the preview
Go deeper on NCT03968978.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03968978.